The aim of this study was to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of a novel anti-mastitis preparation, amoxicillin/sulbactam/prednisolone intramammary infusion (CAIMM), containing 200 mg amoxicillin, 50 mg sulbactam and 10 mg prednisolone per 3 g formulation, in healthy lactating cows after repeated administrations. A parallel study was performed using the available combination product (Synulox ® LC) from Pfizer, with the aim of comparing the two formulations. The concentrations of drugs in quarter milk were determined using the ultra-high performance liquid chromatography tandem mass spectrometric (UPLC-MS/MS) method. No significant difference in the major PK parameters (C max , T max , MRT, t 1/2λ , and AUC last ) was observed. The MIC 90 determined in 106 isolated Staphylococcus spp., 64 Streptococcus spp. and 18 Escherichia coli strains was 0.5, 0.25 and 2 μg/ml, respectively. The PK/PD evaluation showed that the effective duration of action (t > MIC 90 ) for CAIMM (42 ± 2.46 h) was increased by 0.86 times compared with Synulox ® LC (34 ± 3.17 h), but the difference was not significant (P > 0.05). This pharmacokinetic and pharmacodynamic study revealed that CAIMM maintained high concentrations in quarter milk for the three ingredients after repeated intramammary administrations and a similar efficacy was achieved with Synulox ® LC.
Bovine mastitis jeopardises milk production and entails expensive treatment costs so that it brings great economic loss to the dairy industry (Berry et al. 2004; Awale et al. 2012) . It is reported that Staphylococcus aureus, Coagulase-negative staphylococci (CNS), Streptococcus uberis, Streptococcus agalactiae , Streptococcus dysgalactiae and Escherichia coli are common bovine mastitis pathogens (Watts 1988) . Hence, antimicrobial drugs with good efficacy against these organisms are preferred for mastitis therapy during lactation (Cattell et al. 2001) . The intramammary infusion of drugs offers a convenient option for the treatment of mastitis in dairy animals (Gehring and Smith 2006) . A potential advantage of this route is the achievement of high drug concentrations at the site of infection without systemic absorption, thus preventing unwanted side-effects or tissue residues (Gruet et al. 2001) .
Amoxicillin (AMX) is a member of a semisynthetic extended spectrum penicillin group of antibiotics and interferes with bacterial cell wall synthesis. Sulbactam (SUL) is a semi-synthetic compound which inhibits β-lactamases irreversibly and can extend the in vitro spectrum of β-lactam antibiotics. Prednisolone (PSL) belongs to the steroidal anti-inflammatory drugs and mainly aids the reduction in swelling and related pain in in-tramammary treatment (Lees 1991) . It has been observed that AMX alone or in combination with β-lactamase inhibitors is potentially useful for the treatment of mastitis caused by pathogenic organisms (Roberson et al. 2004; Sharma et al. 2010) . A very effective clinical recovery of bovine mastitis was reported in lactating cows treated with intramammary infusion of AMX plus SUL (DeOliveira et al. 2000; Sharma et al. 2010; De and Mukherjee 2012) . Synulox ® LC, a combination drug comprising AMX (200 mg), clavulanic acid (CLAV, 50 mg), and PSL (10 mg) in a 3 g syringe, was developed by Pfizer Pharmaceuticals Inc. (New York, NY, USA.) and used for the treatment of bovine mastitis. However, its application in dairy farms was subjected to great restrictions because of its expensive price in China. Furthermore, the CLAV ingredient in Synulox ® LC is expensive and unstable. Thus, we have developed a novel anti-mastitis preparation, amoxicillin/sulbactam/prednisolone intramammary infusion (CAIMM), in which the ingredient SUL replaces CLAV in Synulox ® LC in order to reduce the product cost and optimise its preparative technology (3 g: AMX 200 mg, SUL 50 mg, and PSL 10 mg). Herein, we investigated the pharmacokinetics (PK) and pharmacodynamics (PD) of CAIMM in lactating dairy cows after repeated administrations, with the aim of providing a new therapeutic agent for the Chinese dairy industry to treat bovine clinical mastitis. Preparation of CAIMM oil suspension. The CAIMM oil suspension was formulated by suspending the active ingredients in the dispersing mixture. Briefly, the dispersing system was first prepared by dissolving suspending agents in dispersing medium, and then AMX, SUL, PSL and wetting agent were dispersed in it using a colloid mill (JM-50c, Shanghai Wangquan pump Co., Ltd, Shanghai, China). The CAIMM formulation was optimised by determining the total score of settling volume ratio after standing for 24 h and redispersibility as the indices. An orthogonal design experiment arranged in an L 9 (3 4 ) orthogonal table was applied to investigate three factors (the amount of suspending agent, wetting agent and antioxidant), in which each factor has three levels. The optimised formulation was hydrogenated castor oil 0.8% (v/v), and vitamin E 0.05% (v/v) .
MATERIAL AND METHODS

Materials
Optimisation of the preparation procedure. A total of 0.24 kg hydrogenated castor seed oil was dissolved in 7.5 l of soybean oil for injection with an electric heater at 85 °C so as to obtain an oily gel, which was transferred into the colloid mill. Another 15 l of soybean oil was added. After that, 2 kg AMX trihydrate, 0.5 kg SUL sodium, and 0.1 kg PSL acetate, 0.3 kg Tween-20, and 0.015 kg vitamin E were added one by one and homogenised for 30 min. Finally, more soybean oil was added into the colloid mill to reach a final volume of 30 l, which was continuously homogenised for an additional 20 min. Finally, the CAIMM oil suspension was enclosed within a glass bottle and disinfected with gamma rays of cobalt 60.
Experimental design. Twelve healthy lactating cows with an average body weight of 510 ± 48.2 kg were provided by a dairy commercial farm around Beijing and randomly divided into two treatment groups (six cows in each group) named as Group Test and Group Cntl. These cows were milked twice daily with milking intervals of 12 h. Milk production was 27.32 ± 5.56 l/day (range 20.2 to 31.3 l/day) and the mean values of days in milking was 180.4 ± 68.6 day. They had not suffered from clinical mastitis for the previous two months. The somatic cell counts (SCC) and bacteriological tests were conducted in four quarters of each cow. The SCC was required to bebelow 200 000 per ml milk and the results of bacteriological tests were negative. Animals were in optimal nutritional condition and had free access to food and water during the entire experimental period. All procedures performed on the experimental animals were approved by the China Agricultural University Animal Care and Use Committee.
After accurate milking and teat disinfection, animals in Group Test were intramammarily administered in a single quarter at a dose of 3 g CAIMM three times at consecutive milking with intervals of 12 h. Animals in Group Cntl were given, in a single quarter, at a dose of 3 g, Synulox ® LC with the same dosing regimen. Milk samples were obtained by manual pressure of the teats and the first three portions of milk was discarded. Quarter milk samples were collected at 0 (pre-administration), 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 40, 46, 52, 60, 72, 84 , and 96 h after the first administration. All samples were stored at -80 °C pending the running of the assay.
Analytical method. Concentrations of AMX and PSL in milk were simultaneously determined by ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) according to our previously described method (Li et al. 2012) . The concentrations of SUL and CLAV were determined using a different analytical method. Samples with concentrations beyond the linear range of the standard curve were quantified after dilution. Details of the validation of the method are summarised in Table 1 .
Isolation of bacteria from milk samples. All bacterial isolates were collected from approximately 300 lactating cows suffering from clinical mastitis in 20 dairy farms surrounding Beijing between January, 2010 and December, 2011. Primary cultures of milk samples were performed by plating 100 μl milk on MacConkey agar for E. coli strain isolation, on Mannitol salt agar for Staphylococcus spp. strain isolation, and on K-F Streptococcus agar (Difco, NJ, USA) for Streptococcus spp. strain isolation. The plates were incubated at 37 °C for 24-48 h. All bacteria isolates were identified by colony morphology, Gram-staining characteristics and API microorganism identification test kits (Biomerieux, Marcy l' Etoile, France). The isolates were then stored at -80 °C in 20% sterile glycerol until further testing.
MIC determination. MIC tests were performed according to the microdilution broth method, as recommended by the Clinical Laboratory Standards Institute (CLSI 2008) . Reference standards of AMX and SUL were dissolved in 0.01M phosphate buffer (pH 7.4) and then diluted in sterile Mueller-Hinton broth. Bacterial strains were prepared by diluting an overnight MH broth culture in buffered saline solution to a density of 0.5 on the McFarland turbidity scale. E. coli (ATCC 25922), S. aureus (ATCC 29213), and S. agalactiae (ATCC 27956) were inoculated as control strains.
Pharmacokinetic analysis. The corresponding milk concentration-time profiles of the drugs AMX, PSL, SUL and CLAV were created using Origin 8.0 (Originlab Corporation, Northampton, USA). A noncompartmental analysis (NCA) was carried out on milk drug concentrations after the last treatment using the WinNonLin Professional 6.2 software (Pharsight Corporation, Mountain View, CA, USA). All results were expressed as mean ± SD. Differences in PK parameters of t 1/2λ (elimination half-life), C max (maximum milk concentration), T max (time to reach C max ), AUC last (area under the milk concentration-time curve for time zero to t), and MRT (mean residence time) between different treatment groups were performed by two-way analysis of variance (ANOVA) using the statistical program SPSS version 17.0 (SPSS Inc., Chicago, USA). Differences were considered statistically significant at P < 0.05.
RESULTS
Preparation of CAIMM oil suspension
After testing and optimising the appropriate ratio of the excipients and preparation process, a novel anti-mastitis preparation-CAIMM was successfully developed. CAIMM is an almost white-to cream-coloured oil suspension that is easy to redisperse with a three-hour setting volume ratio of 100.0%. Syringeability and flowability both con- 
Milk pharmacokinetics
The corresponding milk concentration-time profiles of the drugs AMX, PSL, SUL and CLAV 1.7 μm); gradient elution with a mobile phase of 0.1% formic acid in water (eluent A) and 0.1% formic acid in acetonitrile (eluent B) at a flow rate of 0.3 ml/min; i.e. 0-1 min, 98% A-2% B; 1.5-2.5 min, 15% A-85% B; 3.0-3.5 min, 2% A-98% B; 5.5 min, 98% A AMX and PSL were extracted from 2 ml milk. Then, 6 ml acetonitrile were added to all samples, followed by centrifugation (8603 × g for 10 min), extraction again 1.7 μm); gradient elution with a mobile phase of 0.05% formic acid in water (eluent A) and 0.05% formic acid in acetonitrile (eluent B) at a flow rate of 0.3 ml/min; i.e. 0-0.5 min, 95% A-5% B; 1.5-2.0 min, 5% A-5% B; 3.0 min, 95% A SUL were extracted from 2 ml milk.
Then, 1 ml 0.5M hydrochloric acid and 10 ml ethyl acetate were added, followed by centrifugation at 8603 × g for 10 min, and evaporation to dryness under a stream of nitrogen at 40 °C. The residue was dissolved with 500 μl water. Table 2 .
The results in Table 2 show that the PK parameters of AMX, SUL and PSL of CAIMM are similar to those of Synulox® LC. There was no significant difference (P > 0.05) in any of the PK parameters (t 1/2λ , T max , C max , AUC last and MRT) after the third infusion, indicating that CAIMM had a similar distribution and elimination through the quarter milk compared with Synulox ® LC.
Pharmacokinetic/pharmacodynamic integration
A total of 216 bacteria isolates from approximately 300 lactating cows suffering from bovine clinical mastitis were obtained in this study. The obtained MIC range, MIC 50 and MIC 90 values for AMX and AMX/SUL (4 : 1) toward these isolated strains are summarised in Table 3 . The MICs of isolated strains decreased 2-to 8-fold for AMX/SUL (4 : 1) compared with AMX. The relationship between PK profile and the MIC 90 of the strains is shown in Figure 4 . Milk AMX concentrations were five times higher than the MIC 90 of isolated bovine pathogens at 48 h after the third administration. To illustrate the efficacy of CAIMM, the comparisons of PK/PD parameters were calculated with the MIC and PK parameters of AMX only. The t > MIC 90 and t > MIC 50 of CAIMM against isolated bovine mastitis pathogens were 42 ± 2.46 h and 48 ± 1.12 h, respectively ( Table 2 ). The effective duration of action (t > MIC 90 ) for CAIMM (42 ± 2.46 h) was increased by 0.86 times compared with Synulox® LC (34 ± 3.17 h), but the difference was not significant (P > 0.05). 
DISCUSSION
In China, recent investigations have shown that the annual incidence of clinical mastitis is about 54.3%, and the annual economic loss is estimated to be about 316 million Yuan (Liu 2004; Li et al. 2009 ). It has been reported that E. coli, S. uberis, S. aureus, S. dysgalactiae and S. agalactiae are prevalent pathogens of mastitis (Cheng et al. 2010) . In vivo studies have demonstrated that a bacteriological cure rate of 67% was achieved when intramammary AMX was used against these common pathogens ( Roberson et al. 2004) . In human medicine, several studies have reported the efficacy of a AMX/SUL combination in the treatment of bacterial infections, including E. coli and Acinetobacter baumannii (Bantar et al. 1999 (Bantar et al. , 2009 ). Moreover, the results of our preliminary study showed that a good bactericidal activity in vitro was achieved for the AMX/SUL (4 : 1) combination against these common mastitis pathogens (unpublished results). At present, Synulox ® LC is widely used for the treatment of dairy cow mastitis and a good clinical efficacy is obtained in China. However, its application in dairy farms is subject to great restrictions because of its expensive price. Therefore, it is imperative to develop a novel anti-mastitis preparation in order to reduce mastitis treatment costs, as such a combination product is not available in China.
In this study, a novel CAIMM oil suspension was developed after testing and optimising the appropriate ratio of suspending agents, wetting agent, antioxidant and the active constituents. We have produced three batches of the combination products using colloid mill in the good manufacturing practice (GMP) workshop in the Chinese Animal Husbandry Industry Chengdu Biopharm Itd (Chengdu, China). The volume of each batch was 30 l.
The milk concentration-time relationship was modelled from lactating cows administered the (Figure 4) , which is important when examining two or more drugs in a combination product because the PK characteristics of one active ingredient could be affected by the other ingredients, vehicle or excipients. AMX was generally quantifiable for 60 h after the last administration (Figure 1 ). The milk elimination half-time (t 1/2λ ) of AMX (7.17 ± 3.38 h) in CAIMM was similar to that in Synulox ® LC (5.34 ± 3.30 h, P > 0.05). The different antibiotic and formulation vehicle could contribute to this PK difference in CAIMM and Synulox ® LC. Similar observations have been reported for a plethora of β-lactam antibiotics used in mastitis therapeutics (Whitten and Hanlon 1997; Cagnardi et al. 2010; Zonca et al. 2011) .
PSL, a short-acting glucocorticoid, was basically undetectable in milk after about 12 h post-3 rd administration. Another PK study of Synulox ® LC demonstrated that PSL did not have a prolonged residence time in the milk/udder (about 8-10 h post-infusion, levels of PSL were less than 1 μg/ml) (Synulox Lactating Cow Article 34 referralEuropean Medicines 2011). A rapid elimination half-time of PSL in CAIMM was observed (t 1/2λ = 0.95 ± 0.33 h, Table 2) in this study. PSL was rapidly distributed after the first administration with a peak milk concentration of 76.91 ± 59.51 μg/ml, which decreased to a mean C max value of 26.20 ± 7.56 μg/ ml post-3 rd administration. This indicates that the drug is rapidly released from the formulation and that a high system absorption could be foreseen when PSL is administrated intramammarily.
This study is the first to report the PK characteristic of SUL in lactating cows after repeated intramammary administration. Metabolic studies using UPLC-TOF/MS showed that SUL was mainly eliminated in the way of the parent compound in quarter milk samples. The metabolites did not contribute significantly to its elimination (data not shown). After intramammary administration of CAIMM containing 50 mg of SUL in a single quarter of lactating cows, the mean peak concentration was 134.7 ± 96.5 μg/ml and the time to C max (t max ) was 2.33 ± 0.82 h. The mean elimination half-time and AUC last did not have a significant difference from those of CLAV at the same dose (Table 2) . To better understand drug efficacy and residues within the bovine udder, a more comprehensive understanding of milk drugs concentrations in the different compartments of the mammary gland 
